Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

10 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The effect of concomitant beta-blocker use on survival in patients with metastatic renal cell carcinoma treated with a vascular endothelial growth factor receptor inhibitors in the first line.
Korkmaz M, Eryılmaz MK, Koçak MZ, Er MM, Hendem E, Demirkıran A, Araz M, Artaç M. Korkmaz M, et al. Among authors: hendem e. Eur J Clin Pharmacol. 2024 Jun;80(6):941-947. doi: 10.1007/s00228-024-03668-8. Epub 2024 Mar 13. Eur J Clin Pharmacol. 2024. PMID: 38478093
Efficacy of Capecitabine and Temozolomide Regimen in Neuroendocrine Tumors: Data From the Turkish Oncology Group.
Ünal Ç, Azizy A, Karabulut S, Taştekin D, Akyıldız A, Yaşar S, Yalçın Ş, Çoban E, Evrensel T, Kalkan Z, Oruç Z, Derin S, Turna ZH, Bayram D, Köş FT, Şendur MAN, Sever N, Ercelep Ö, Seyyar M, Kefeli U, Uygun K, Özçelik M, Ön S, Şanlı UA, Canaslan K, Ünek İT, Yücel KB, Özdemir N, Yazıcı O, Güzel HG, Salim DK, Göksu SS, Tatlı AM, Ordu Ç, Selvi O, Sakin A, Büyükbayram ME, Dursun B, Ürün Y, Arak H, Ağdaş G, Uğraklı M, Hendem E, Eryılmaz MK, Bilgin B, Topçu A, Şimşek M, Büyükşimşek M, Akay B, Erdal GŞ, Karataş F, Alan Ö, Çağlayan M, Kahvecioğlu FA, Demirci A, Paksoy N, Çetin B, Gümüş M, Ak N, Aydınalp Y, Paydaş S, Güven DC, Kılıçkap S, Sağlam S. Ünal Ç, et al. Among authors: hendem e. Oncologist. 2023 Oct 3;28(10):875-884. doi: 10.1093/oncolo/oyad257. Oncologist. 2023. PMID: 37676712 Free PMC article.
Comparison of the Efficacy and Safety of 3 Months of CAPOX Followed by 3 Months of Capecitabine and 6 Months of CAPOX/FOLFOX in the Adjuvant Treatment of Low-Risk Stage III Colon Cancer Treated Surgically.
Bardakci M, Demirtas Esmer D, Hafizoglu E, Yaslikaya S, Genc TB, Ozcelik M, Erdat EC, Hendem E, Buyukbayram ME, Alaca Topcu Z, Kalkan Z, Yildirim N, Celebi A, Ergun Y, Paydas S, Tatli AM, Karakas H, Koseci T, Sendur MAN. Bardakci M, et al. Among authors: hendem e. Oncology. 2023;101(11):723-729. doi: 10.1159/000531722. Epub 2023 Jun 28. Oncology. 2023. PMID: 37379817
The effect of concomitant proton pump inhibitor use on survival outcomes of Nivolumab-treated renal cell carcinoma patients: a multicenter study.
Uğraklı M, Koçak MZ, Dinç G, Genç TB, Çağlayan M, Uğraklı S, Hendem E, Er MM, Çağlayan D, Eryılmaz MK, Araz M, Geredeli Ç, Tatlı AM, Eren OÖ, Artaç M. Uğraklı M, et al. Among authors: hendem e. J Cancer Res Clin Oncol. 2023 Sep;149(11):9183-9189. doi: 10.1007/s00432-023-04844-6. Epub 2023 May 15. J Cancer Res Clin Oncol. 2023. PMID: 37184681
Does red blood cell distribution width predict prognosis in metastatic renal cell carcinoma patients using first-line vascular endothelial growth factor receptor tyrosine kinase inhibitor therapy?
Korkmaz M, Eryılmaz MK, Koçak MZ, Er MM, Hendem E, Demirkıran A, Araz M, Karaağaç M, Artaç M. Korkmaz M, et al. Among authors: hendem e. J Cancer Res Ther. 2023 Apr;19(Supplement):S0. doi: 10.4103/jcrt.jcrt_898_22. J Cancer Res Ther. 2023. PMID: 37147975 Free article.
Ribociclib-induced hepatotoxicity.
Er MM, Araz M, Hendem E, Eryılmaz MK, Artaç M. Er MM, et al. Among authors: hendem e. J Oncol Pharm Pract. 2023 Jul;29(5):1275-1277. doi: 10.1177/10781552231154009. Epub 2023 Feb 10. J Oncol Pharm Pract. 2023. PMID: 36762416
Is pancreatic giant cell tumor resistant to standard chemotherapy?
Çağlayan D, Karakurt Eryilmaz M, Korkmaz M, Karaağaç M, Hendem E, Artaç M. Çağlayan D, et al. Among authors: hendem e. Anticancer Drugs. 2022 Sep 1;33(8):758-760. doi: 10.1097/CAD.0000000000001331. Epub 2022 Aug 10. Anticancer Drugs. 2022. PMID: 35946539